Acenocoumarol Tablets

This product is a synthetic substitute of dicoumarol. Its chemical structure is similar to that of vitamin K. It competitively antagonizes vitamin K, hindering the latter's utilization and inhibiting the synthesis of prothrombin and coagulation factors II, VII, IX, and X in the liver. It is the most potent oral anticoagulant among dicoumarols. Its effect is faster than that of dicoumarol, but its duration is shorter. It has no effect on synthesized prothrombin and coagulation factors.

This product contains acenocoumarol (C19H15NO6). Molecular formula: C19H15NO6 Molecular weight: 353.34

This product is white tablets.

It is used to prevent and treat intravascular thrombotic diseases, such as venous thrombosis, pulmonary embolism, myocardial infarction and embolism caused by atrial fibrillation. It is especially suitable for those who maintain long-term anticoagulation. For acute arterial occlusion, heparin should be used to control symptoms first, and then this product should be used.

Oral dosage: 4-8 mg on the first day, taken in divided doses; 2-4 mg on the second day; maintenance dose: 2.5-5 mg per day, taken in divided doses.

Oral overdose can cause bleeding, the most common sites of bleeding are the skin, mucous membranes, gastrointestinal tract, and urinary tract, and there are also phenomena such as hematuria, gingival bleeding, epistaxis, ecchymosis, and hemoptysis. Occasionally, dizziness, nausea, diarrhea, skin allergies, severe persistent headaches, back pain, abdominal pain, etc. may occur.

It is contraindicated for use in patients with bleeding tendency, gastrointestinal ulcers, severe renal insufficiency, within three days after delivery or surgery, and in late pregnancy and lactating women.

Precautions during pregnancy and lactation: It is forbidden to use within three days after delivery, in late pregnancy and during lactation.

1. Drugs that can enhance the anticoagulant effect when used in combination with this product include: ⑴ drugs that can compete with this product for plasma protein binding, thereby increasing the free amount of di-coumarin, such as aspirin, phenylbutazone, hydroxyphenylbutazone, mefenamic acid, chloral hydrate, clofibrate (clofibrate), sulfonamides, probenecid, etc.; ⑵ drugs that inhibit liver microsomal enzymes, thereby reducing the metabolism of this product and increasing its efficacy, such as chloramphenicol, allopurinol, monoamine oxidase inhibitors, metronidazole (metronidazole), cimetidine, etc.; ⑶ drugs that reduce the absorption of vitamin K and affect the synthesis of prothrombin, such as various broad-spectrum antibiotics, long-term use of liquid paraffin or cholestyramine (cholestyramine), etc.; ⑷ drugs that can promote the use of this product ⑸ Drugs that bind to platelet receptors, such as quinidine, thyroxine, anabolic steroids, and phenformin; ⑸ Drugs that interfere with platelet function and promote anticoagulation, such as high-dose aspirin, salicylates, prostaglandin synthase inhibitors, chlorpromazine, diphenhydramine, etc.; ⑹ In addition, drugs that can enhance anticoagulation include propylthiouracil, diazoxide, disopyramide, oral hypoglycemic drugs, sulfinpyrazone (anti-gout drugs), etc.; the mechanism is not clear; ⑺ Adrenal cortical hormones and phenytoin sodium can both increase and weaken the anticoagulant effect, and there is a risk of gastrointestinal bleeding. Generally, they are not used together; ⑻ It cannot be used in combination with nekinase and urokinase, otherwise it is easy to cause critical bleeding. 2. Drugs that can weaken the anticoagulant effect when used in combination with this product: ⑴ Inhibit the absorption of oral anticoagulants, including antacids, laxatives, griseofulvin, rifampicin, glutethimide (Daomen Neng), meprobamate (Anning), etc.; ⑵ Vitamin K, oral contraceptives and estrogen, etc., compete with related enzyme proteins and promote the synthesis of factors II, VII, IX, and X.

Keep away from light and store in a sealed container.

1mg

Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

• Founded in:

  1993-10-23

• Address:

  No. 905, Xinjinqiao Road, China (Shanghai) Pilot Free Trade Zone

• Tax NO.:

  91310000133742534B

• Registered Funds:

  1,191,611,312 yuan

• Website:

  Log in to view

• Email:

  Log in to view